Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a report released on Sunday. The firm set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

Accelerate Diagnostics Trading Down 1.8 %

Accelerate Diagnostics stock opened at $1.10 on Friday. The firm has a market capitalization of $27.55 million, a PE ratio of -0.38 and a beta of 0.55. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $2.09. The firm has a 50-day moving average price of $1.18 and a 200-day moving average price of $1.50.

Hedge Funds Weigh In On Accelerate Diagnostics

Institutional investors and hedge funds have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd purchased a new position in shares of Accelerate Diagnostics during the 3rd quarter worth approximately $34,000. Geode Capital Management LLC boosted its holdings in Accelerate Diagnostics by 6.9% in the fourth quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock valued at $163,000 after purchasing an additional 8,777 shares in the last quarter. Renaissance Technologies LLC lifted its position in Accelerate Diagnostics by 160.6% in the fourth quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock valued at $128,000 after acquiring an additional 65,984 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Accelerate Diagnostics in the 4th quarter valued at about $27,000. 17.14% of the stock is currently owned by institutional investors and hedge funds.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.